

High prevalence of genetic abnormalities in Middle Eastern patients with idiopathic non-obstructive azoospermia

Marwan Alhalabi · Mazen Kenj · Fawza Monem ·
Zaina Mahayri · Ghalia Abou Alchamat ·
Ammar Madania

Received: 2 January 2013 / Accepted: 9 April 2013 / Published online: 25 April 2013
© Springer Science+Business Media New York 2013

Abstract

Introduction Our objective is to detect the frequency and types of major genetic abnormalities of idiopathic non-obstructive azoospermia (NOA) to give appropriate genetic counseling before assisted reproductive techniques (ART) in Middle East and to compare the frequencies with other regions of the world.

Material and methods A total of 880 Middle Eastern patients with NOA were recruited in this multicenter study for genetic evaluation prior to use of ART. Karyotyping was performed on peripheral blood lymphocytes according to standard G-banding methods, polymerase chain reaction (PCR) was performed to screen the microdeletions in the AZF region of the Y chromosome.

Capsule Men with Non-obstructive azoospermia need genetic testing and counseling prior to assisted reproduction.

M. Alhalabi · M. Kenj
Assisted reproduction unit, Orient Hospital,
Damascus, Syria

M. Alhalabi (✉)
Division of Reproductive Medicine and Embryology,
Faculty of Medicine, Damascus, Syria
e-mail: halabi.mj@me.com

G. Abou Alchamat
Department of Reproductive Medicine and Embryology,
Damascus University, Damascus, Syria

F. Monem · Z. Mahayri
Al Assad University Hospital, Damascus University,
Damascus, Syria

A. Madania
Department of Radiation Medicine,
Atomic Energy Commission of Syria, Damascus, Syria

Results The present study shows that the total prevalence of genetic abnormalities is 28.41 %, including 184 patients (20.91 %) with chromosome disorder and 66 patients (7.5 %) with Y chromosome microdeletions. The most prevalent chromosome abnormality is Klinefelter's syndrome, which includes 161 patients (18.3 %), 7 patients had XX reversal male sex (0.8 %), 2 patients had 47XYY (0.23 %) and 2 patients had 45XO/46XY (0.23 %). Structural abnormalities occurred in 12 patients (1.36 %).

Conclusions The high prevalence of genetic abnormalities (28.41 %) in our study strongly suggests the need for routine genetic testing and counseling prior to assisted reproduction in such population with idiopathic infertility, as a result may help determine the prognosis, as well as the choice of ART. Moreover it allows specific pre-implantation genetic testing to minimize the risk of transmitting genetic defects to offspring.

Keywords Genetic abnormality · Non-obstructive Azoospermia · Microdeletion

Introduction

Infertility is a very common health problem, affecting approximately 15–20 % of couples who attempt pregnancy [1]. Male factor is assumed to be responsible in about 40–50 % of the infertile couples [2–5]. About 15 % of the infertile men may carry a genetic abnormality, including numerical and structural chromosomal abnormalities [6, 7]. The frequency of chromosomal abnormalities in subfertile males is estimated to be 2–10 % [8, 9], and may reach 10–19 % in azoospermia cases [10].

Azoospermia is defined as complete absence of sperm from ejaculate and approximately occurs in 10–15 % of infertile

men with abnormal semen analysis [11]. Azoospermia is classified as obstructive and non-obstructive, although in some clinical protocols aetiologies for azoospermia fall into pre-testicular, testicular and post-testicular categories [12, 13].

Among the genetic abnormalities found in azoospermia men, the most frequent one being the 47, XXY karyotype that characterizes the klinefelter syndrome [2, 14]. Microdeletions of the Y chromosome removing the azoospermia factor (AZF) region are the most frequent genetic cause of spermatogenic failure after the klinefelter's syndrome [4, 15–17]. The AZF region is further subdivided into three non-overlapping regions defined as AZFa, AZFb and AZFc [4, 18, 19]. Furthermore, recently a fourth region, AZFd, has been proposed between AZFb and AZFc. So far at least 12 genes have been isolated from these regions [20]. Several genes located in the AZF region are expressed in the testes and could therefore be viewed as “AZF candidate genes”. Figure 1 depicts the three different AZF regions of the Y chromosome.

Patients with microdeletions restricted to AZFd may present mild oligozoospermia or abnormal sperm morphology. But the patients with microdeletions restricted to AZFa usually result in patients with sertoli cell only syndrome (SCOS), whereas microdeletions restricted to AZFb or

AZFc can result in patients with phenotypes, which range from SCOS to moderate oligozoospermia [22].

Structural chromosomal abnormalities can also cause spermatogenic failure. Structural abnormalities include inversions, balanced translocations and additional chromosomal material. Reciprocal and Robertsonian translocations are also found in azoospermic patients [23].

The aim of this multicenter study is to detect the frequency and types of major genetic abnormalities of idiopathic non-obstructive azoospermia (NOA) to give appropriate genetic counseling before assisted reproductive techniques (ART) in Middle East and to compare the frequencies with other regions of the world.

Material and methods

A total of 880 Middle Eastern patients with NOA were prospectively recruited in this multicenter study for genetic evaluation from January 2008 to January 2011 at faculty of medicine in Damascus university (253 patients), Orient hospital (385 patients), Al-Assad university hospital (87 patients) and department of radiation medicine in atomic energy commission (155 patients). The patients originate from Syria, Iraq, Palestine, Lebanon, Jordan, Saudi Arabia, Qatar and United Arab Emirates.

The mean age of the patients (\pm SD) was 32.6 ± 6.8 . All Participants gave informed consent, according to the protocol approved by local Ethics Committee at Damascus University and health ministry. Routine Clinical and laboratory tests were performed on all patients, Including Semen Analysis, Hormones, Karyotype and investigation of Y chromosome microdeletions.

Semen analysis was performed according to world health organization criteria (WHO laboratory manual for the examination of human semen and semen-cervical interaction, 1999). Clinical examination was performed in all of the patients for anatomical integrity of genital system, and we excluded all the patients who had any history of childhood disease, environmental or radiation exposure, prescription drug usage that could account for their infertility, and other pathologies as varicocele or cryptorchidism. The diagnosis of non-obstructive azoospermia was based on clinical finding and several parameters as FSH, testicular volume and histopathology of a previous testicular biopsy (if available) although no standard method was used. Hormone analysis including follicle stimulating hormone (FSH), luteinizing hormone (LH), Prolactin (PRL) and testosterone were also done by using Enzyme-Linked Immuno-Sorbent Assay (ELISA).

Karyotype analysis was performed using G-Banding methods, and at least 30 peripheral blood metaphases were analyzed for each patient. The number of analyzed metaphases was increased to 100 whenever necessary. All




Fig. 1 Diagram shows the AZF region of Y chromosome [21]

chromosomal abnormalities have been reported in accordance with the current international standard nomenclature.

Screening for microdeletions in AZF region of Y chromosome was done by polymerase chain reaction (PCR). Genomic DNA was extracted from peripheral blood leukocytes using QIAamp DNA blood mini kit (Qiagen, Germany) according to manufacturer’s instruction. Extracted DNA concentration and purity were measured using BioPhotometer Plus (Eppendorf, Germany). The following 20 sequence tagged sites (STS markers) were analyzed using Y chromosome deletion detection system, version 2 kit (Promega, USA):

- SY81, SY86, SY84, SY182 (AZF a)
- SY121, SYPR3, SY124, SY127, SY128, SY130, SY133, SY134 (AZF b).
- SY242, SY208, SY254, SY254, SY255, SY157 (AZF c).
- SY145, SY152 (Proximal AZFc (AZFd)).
- SY14 (SRY). And SMCX locus, ZFX/ZFY were used as internal controls.

5 Multiplex PCRs was performed for each sample using mastercycler® thermal cycler machine (Eppendorf, Germany). With the following program: 94 °C for 2 min, then 94 °C for 1 min, 57 °C for 30 s, 72 °C for 1 min (35 cycles) and a final extension 72 °C for 5 min. PCR products were electrophoresed on 3 % LMP agarose gel (Promega, USA) in 1X TBE buffer containing 0.5 µg/ml ethidium bromide, and a running buffer 1X TBE buffer containing 0.5 µg/ml ethidium bromide . 5 V\cm for 35 min.

Gel was visualized using UV transilluminator (320 nm) and photographed using gel documentation system. Normal male genomic DNA control and No DNA control were performed with each set of samples. DNA extraction and Mix preparation were performed by female technician. Unamplified STS was confirmed by additional two experiments.

Results

Genetic abnormalities were found in 28.41 % of all non-obstructive azoospermic men studied, Including 184 patients (20.91 %) with karyotype abnormalities as shown in Table 1, and 66 patients (7.5 %) with Y-chromosome microdeletions as shown in Table 2.

Variable translocations and additional chromosomal material occurred in 12 patients (1.36 %) as shown in Table 3.

Discussion

The most prevalent chromosomal abnormality in our study was klinefelter’s syndrome (KS), which including 161

Table 1 The Karyotype of the patients with idiopathic NOA

| Karyotype | Number | Rate |
|--------------------------|--------|-------|
| 46, XY | 696 | 79.09 |
| 47, XXY | 143 | 16.25 |
| 47, XXY/46, XY | 18 | 2.05 |
| 46, XX Male | 7 | 0.8 |
| 47,XXY | 2 | 0.23 |
| 45, XO/46, XY | 2 | 0.23 |
| Structural abnormalities | 12 | 1.36 |

patients (18.3 %), 143 patients (16.25 %) were non-mosaic and 18 patients (2.05 %) were mosaic.

Klinefelter’s Syndrome (KS) is the most common abnormality of sexual differentiation, and occurs in approximately 1 in 500 live births. KS is a form of primary testicular failure with testicular hypotrophy and elevated gonadotropin plasma levels, and it represents the most common form of male hypogonadism [24]. Other studies showed that the prevalence of KS among NOA men is very high, up to 10 % [25]. It has always been assumed that more than 90 % of non-mosaic 47,XXY males are azoospermic. In their series, 74.4 % of mosaic 47,XXY/46,XY patients were azoospermic, whereas the remaining had severe oligospermia [2]. The result of the other international studies in the literature revealed an average frequency of 15.1 % (ranged from 4.2 % to 33 %) chromosomal abnormalities in men with NOA as shown in Table 4. Moreover, the result of the other regional studies reported an average frequency of 14.9 % (ranged from 4.2 % to 33 % also) chromosomal abnormalities in NOA patients [4, 5, 16, 28, 34, 36–38, 40, 41, 43].

Y chromosome microdeletions have been increasing interest to clinician since assisted reproductive techniques were introduced to the main treatment option for severe male factor infertility. The frequency of microdeletions in the literature was internationally reported to be in the range of 1.9 % to 55.6 % with an average frequency of 10.8 % as shown in Table 5. Nevertheless this frequency of microdeletions in the regional studies was reported to be in the range of 1.9 % to 51.2 % with an average frequency of 10.5 % [4, 5, 16, 36, 37, 40, 51, 54].

Table 2 Distribution of microdeletions in AZF region

| AZF region | Number | Rate |
|------------|--------|-------|
| AZFa | 6 | 9.09 |
| AZFb | 22 | 33.33 |
| AZFc | 18 | 27.27 |
| AZFb+c | 11 | 16.67 |
| AZFb+d | 6 | 9.09 |
| AZFd+c | 2 | 3.03 |
| AZFb+d+c | 1 | 1.52 |

AZF Azoospermia factor

Table 3 Structural abnormalities of the patients with idiopathic NOA

| Karyotype | Number |
|---|--------|
| 45, XY t(14; 15) | 2 |
| 46, XY t(7; 14) | 2 |
| 46, XY t(14;21) | 1 |
| 46, XY t(9; X) | 1 |
| 46, XY t(15; 11) | 1 |
| 46, XY t(14; 14) | 1 |
| 46, XY t(13; 14) | 1 |
| 46, XY t(5; 11) | 1 |
| <i>t</i> chromosomal translocation; <i>add</i> additional chromosome material | 1 |
| 46, XY add(15) | 1 |
| 46, XY add(9) | 1 |

In the present study, the frequency of AZF microdeletions was 7.5 % in non-obstructive azoospermic men, which is little lower than the average value. And microdeletions in the AZFb region were the most prevalent (60.61 %), followed by the AZFc (48.48 %), AZFd (13.64 %) and AZFa (9.09 %) respectively. All cases of microdeletions in AZFa region were isolated, but other microdeletions were combined or isolated. None of patients showed individual deletion in AZFd region,

however deletion in this region was observed in combination with deletions in other AZF regions.

Our finding is in agreement with the study of Mirfakhraie et al. [54] who reported that 12 % of men with NOA had Y microdeletions and the deletion in AZFb region was the most frequent (66.7 %) followed by AZFc (41.7 %), AZFd (33.3 %) and AZFa (8.3 %), respectively. These are in accordance with the finding in Shanghai [46] where majority of microdeletions in men with NOA were in AZFb region. Another study [56] showed that microdeletions of AZF region occur with different frequency, it has been suggested that AZFc is the most frequently deleted region (60 %), followed by deletions of the AZFb and combined deletions involving different AZF region (35 %). AZFa deletions are extremely rare (5 %) and isolated deletions have been reported.

It is suggested that complete deletion of AZFa region may result in complete sertoli cell only syndrome (SCOS) and azoospermia. Identification of deletions in this region is very important since it is impossible to retrieve testicular sperm for Intracytoplasmic sperm injection [57–60].

Most microdeletions of AZF region are de novo events, due to deletions occurring in germ cells or in early cleavage

Table 4 Review of the literature of the chromosomal abnormalities in non-obstructive azoospermia

| Author | Year | Region | Cases | Chromosome abnormality | | |
|----------------------------|------|-------------|-------|------------------------|-----------------|-------------|
| | | | | Gonosomal (n/%) | Autosomal (n/%) | Total (n/%) |
| Rucker et al. [26] | 1998 | USA | 101 | 13 (12.9) | 8 (7.9) | 21 (20.8) |
| Tuerlings et al. [27] | 1998 | Netherlands | 62 | | | 4 (6.5) |
| Gunduz et al. [28] | 1998 | Turkey | 41 | | | 14 (34.1) |
| Kleiman et al. [4] | 1999 | Israel | 105 | 5 (4.8) | 5 (4.8) | 10 (9.5) |
| Dohle et al. [7] | 2002 | Netherlands | 37 | 3 (8.1) | 1 (2.7) | 4 (10.8) |
| Vicdan et al. [16] | 2004 | Turkey | 119 | | | 5 (4.2) |
| Rao et al. [29] | 2004 | India | 99 | | | 7 (7.1) |
| Nagvenkar et al. [30] | 2005 | India | 42 | 5 (11.9) | 1 (2.4) | 6 (14.3) |
| Zhou-Cun et al. [31] | 2006 | China | 256 | | | 31 (12.1) |
| Pina-Neto et al. [32] | 2006 | Brazil | 60 | 12 (20) | – | 12 (20) |
| Meza-Espinoza et al. [33] | 2006 | Mexico | 227 | 41 (18.1) | 2 (0.9) | 43 (18.9) |
| Samli et al. [34] | 2006 | Turkey | 383 | 38 (10) | 9 (2.3) | 47 (12.3) |
| Vutyavanich et al. [5] | 2007 | Turkey | 50 | 4 (8) | 1 (2) | 5 (10) |
| Martinez-garza et al. [35] | 2008 | Mexico | 50 | 7 (14) | 1 (2) | 8 (16) |
| Balkan et al. [36] | 2008 | Turkey | 52 | 7 (13.5) | – | 7 (13.5) |
| Ceylan et al. [37] | 2009 | Turkey | 30 | 10 (33.3) | – | 10 (33.3) |
| Akgul et al. [38] | 2009 | Turkey | 86 | 15 (17.4) | – | 15 (17.4) |
| Ng et al. [39] | 2009 | Hong Kong | 71 | 13 (18.3) | 2 (2.8) | 15 (21.1) |
| Kumtepe et al. [40] | 2009 | Turkey | 1,214 | | | 199 (16.4) |
| Kosar et al. [41] | 2010 | Turkey | 92 | 5 (5.4) | – | 5 (5.4) |
| Mafra et al. [42] | 2011 | Brazil | 43 | 5 (11.6) | – | 5 (11.6) |
| Akbari et al. [43] | 2012 | Iran | 132 | 27 (20.4) | – | 27 (20.4) |
| Total | | | 3,309 | | | 498 (15.1) |
| Our Study | 2013 | Middle East | 880 | 172 (19.5) | 12 (1.4) | 184 (20.9) |

Table 5 Review of the literature of Y-chromosome microdeletions in non-obstructive azoospermia

| Author | Year | Region | Cases | Y-microdeletions (n/%) | Most prevalent pattern |
|----------------------------|------|--------------------|-------|------------------------|------------------------|
| Kremer et al. [44] | 1997 | Netherlands | 19 | 9 (47.4) | AZFc |
| Foresta et al. [45] | 1998 | Italy | 18 | 10 (55.6) | AZFc |
| Rucker et al. [26] | 1998 | USA | 183 | 17 (9) | AZFc |
| Kleiman et al. [4] | 1999 | Israel | 105 | 7 (6.7) | AZFc |
| Dohle et al. [7] | 2002 | Netherlands | 37 | 3 (8.1) | AZFc |
| Tse et al. [46] | 2002 | Hong Kong | 59 | 5 (8.5) | AZFc |
| | 2002 | Shanghai | 135 | 9 (6.7) | AZFb |
| SaoPedro et al. [47] | 2003 | Brazil | 29 | 2 (6.9) | AZFc |
| Vicdan et al. [16] | 2004 | Turkey | 119 | 17 (14.3) | AZFc |
| Roa et al. [29] | 2004 | India | 99 | 11 (12) | AZFc |
| Zhou-Cun et al. [31] | 2006 | China | 256 | 38 (14.8) | AZFc |
| Pina-Neto et al. [32] | 2006 | Brazil | 60 | 4 (6.7) | AZFc |
| Omrani et al. [48] | 2006 | Azerbaijan | 60 | 18 (30) | AZFc |
| Vutyavanich et al. [5] | 2007 | Turkey | 50 | 5 (10) | AZFc |
| Arruda et al. [49] | 2007 | Brazil | 23 | 10 (43.5) | AZFa |
| Imken et al. [50] | 2007 | Morocco | 48 | 4 (8.3) | AZFc |
| Malekasgar et al. [51] | 2008 | Iran | 31 | 16 (51.2) | AZFc |
| Martinez-garza et al. [35] | 2008 | Mexico | 50 | 6 (12) | |
| Balkan et al. [36] | 2008 | Turkey | 52 | 1 (1.9) | AZFc |
| Ceylan et al. [37] | 2009 | Turkey | 30 | 5 (16.7) | AZFc |
| Ng et al. [39] | 2009 | Hong Kong | 71 | 6 (8.5) | AZFc |
| Kumtepe et al. [40] | 2009 | Turkey | 1,214 | 115 (9.5) | AZFc |
| Stahl et al. [52] | 2010 | USA | 1,153 | 120 (10.4) | AZFc |
| Wang et al. [53] | 2010 | Northeastern China | 219 | 20 (9.2) | AZFc |
| Mirfakhraie et al. [54] | 2010 | Iran | 100 | 12 (12) | AZFb |
| Behulova et al. [55] | 2011 | Slovakia | 239 | 8 (3.6) | AZFc |
| Total | | | 4,680 | 506 (10.8) | AZFc |
| Our Study | 2013 | Middle East | 880 | 66 (7.5) | AZFb |

stages. We believe that the deletions in our study were de novo too, whereas all deleted patients were born after natural conceptions, unfortunately, we could not perform the genetic testing for all fathers, only 17 fathers did the Y-Chromosome microdeletions investigation and all of them were normal.

It is clear that the frequency and pattern of microdeletions in NOA are variable (possible ethnic or geographic factors), but the most frequent place of deletions was AZFb region in our study. We may conclude that genes located in the AZFb region were more involved in fertility process in Middle Eastern patients with NOA [54], as a result may help determine the prognosis of sperm retrieval. This is contrary to previous reports in which AZFc deletion was reported to be the most frequent deletion in NOA [4, 5, 16, 36, 37, 40, 51].

Y chromosome microdeletion analysis should routinely be offered to all men with NOA. There are several considerations that support a routine assessment of Y deletion. Firstly, a positive test would provide a firm diagnosis of the man's

problem. Secondly, knowledge of the type of Y deletion may assist the clinician in determining the best type of assisted reproduction. Thirdly, couples should be offered this information, as they must understand that their male offspring will almost certainly be subfertile and require reproductive monitoring from the time of sexual maturation [61].

Accordingly, men with Y microdeletions are often infertile, but many can still father children through ICSI using the few sperms present in semen or isolated directly from the testis. Modern sperm recovery techniques have made it possible to help men with NOA to achieve fatherhood [62]. Assisted reproductive techniques have given the chance of having a child to infertile males with NOA.

However, using the intracytoplasmic sperm injection (ICSI) in this group with high genetic abnormalities ratio may increase the inheritance of paternal genetic disorders to offspring [41]. It occurs because the presence of the structural chromosomal abnormality predisposes to abnormal segregation in meiosis. Alternate segregation in male

gametes has been reported and may result in fertilization failure or poor embryonic development [63, 64]. In these cases, the couple should be offered pre-implantation genetic diagnosis (PGD) whenever possible [47].

A relationship between structural chromosomal abnormalities and infertility has been reported among azoospermic men [30]. In our study reciprocal translocations were seen in 10 cases (1.14 %) and additional chromosomal materials were seen in two cases (0.23 %). It is hypothesized that balanced translocations interfere with normal chromosome pairing and segregation at meiosis, thus providing a potential for formation of unbalanced gametes and subsequent unbalanced abnormal offspring [31].

Couples experiencing NOA who are interested in pursuing assisted reproduction are encouraged to discuss genetic testing with their physicians or healthcare providers and to consider undergoing genetic counseling [65].

Although our results reflect a regional pattern of those referrals, comparison of our results with the review of the literature shows a relatively higher incidence of chromosomal abnormalities in idiopathic NOA in the Middle East, which may be due to high incidence of consanguinity, geographic and ethnic origins of the studied population, since our samples were collected from eight countries of Middle East region. These variations may reflect selection bias due to our referral pattern and study design including the composition of the study population and sample size.

In conclusion, our results support that the high prevalence of genetic abnormalities 28.41 % in non-obstructive azoospermic men, strongly suggests the need for routine genetic testing and counseling prior to assisted reproduction in such population with idiopathic infertility, as a result may help determine the prognosis, as well as the choice of ART. Moreover, it allows specific pre-implantation genetic testing to minimize the risk of transmitting genetic defects to offspring.

Implications for patients

This prospective cohort study investigates the prevalence of genetic abnormalities (Karyotype and Y-Chromosome microdeletions) in 880 infertile Middle Eastern men with non-obstructive azoospermia (NOA) referred to several academic centers within Syria.

Its implications include having a high frequency of genetic abnormalities (28.41 %) among this population (NOA men) in this region, suggesting strongly the need for routine genetic testing and counseling prior to assisted reproduction in such patients, and gaining further insight into the etiology of NOA by comparing results with internationally published data.

Acknowledgement We appreciate the collaboration of the patients and express gratitude to Dr. Sawsan Alsamawi, Dr. Adnan Alkhatib,

Dr. Jamal Alsharif, Dr. Ahmad Taha and Professor Ahmad Othman for their kind Collaboration. We also acknowledge the scientific research committee of the faculty of medicine and the research deputy of Orient Hospital for providing grant to carry out this study

References

- Mittal RD et al. Y chromosome micro-deletions in idiopathic infertility from Northern India. *Ann Genet.* 2004;47(4):331–7.
- Ferlin A, Arredi B, Foresta C. Genetic causes of male infertility. *Reprod Toxicol.* 2006;22(2):133–41.
- Shefi S, Turek PJ. Definition and current evaluation of subfertile men. *Int Braz J Urol.* 2006;32(4):385–97.
- Kleiman SE et al. Genetic evaluation of infertile men. *Hum Reprod.* 1999;14(1):33–8.
- Vutyavanich T et al. Frequency of Y chromosome microdeletions and chromosomal abnormalities in infertile Thai men with oligozoospermia and azoospermia. *Asian J Androl.* 2007;9(1):68–75.
- de Kretser DM. Male infertility. *Lancet.* 1997;349(9054):787–90.
- Dohle GR et al. Genetic risk factors in infertile men with severe oligozoospermia and azoospermia. *Hum Reprod.* 2002;17(1):13–6.
- Van Assche E et al. Cytogenetics of infertile men. *Hum Reprod.* 1996;11 Suppl 4:1–24. discussion 25–6.
- Koulikischer L, Schoysman R. Chromosomes and human infertility. I. Mitotic and meiotic chromosome studies in 202 consecutive male patients. *Clin Genet.* 1974;5(2):116–26.
- Chandley AC. The chromosomal basis of human infertility. *Br Med Bull.* 1979;35(2):181–6.
- Ezeh UI. Beyond the clinical classification of azoospermia: opinion. *Hum Reprod.* 2000;15(11):2356–9.
- Sharif K. Reclassification of azoospermia: the time has come? *Hum Reprod.* 2000;15(2):237–8.
- Ezeh UI et al. Establishment of predictive variables associated with testicular sperm retrieval in men with non-obstructive azoospermia. *Hum Reprod.* 1999;14(4):1005–12.
- McLachlan RI et al. Genetic disorders and spermatogenesis. *Reprod Fertil Dev.* 1998;10(1):97–104.
- Britton-Jones C, Haines CJ. Microdeletions on the long arm of the Y chromosome and their association with male-factor infertility. *Hong Kong Med J.* 2000;6(2):184–9.
- Vicdan A et al. Genetic aspects of human male infertility: the frequency of chromosomal abnormalities and Y chromosome microdeletions in severe male factor infertility. *Eur J Obstet Gynecol Reprod Biol.* 2004;117(1):49–54.
- Hucklenbroich K et al. Partial deletions in the AZFc region of the Y chromosome occur in men with impaired as well as normal spermatogenesis. *Hum Reprod.* 2005;20(1):191–7.
- Bache I et al. An excess of chromosome 1 breakpoints in male infertility. *Eur J Hum Genet.* 2004;12(12):993–1000.
- Hellani A et al. Y chromosome microdeletions in infertile men with idiopathic oligo- or azoospermia. *J Exp Clin Assist Reprod.* 2006;3:1.
- Reijo R et al. Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. *Nat Genet.* 1995;10(4):383–93.
- Foresta C, Moro E, Ferlin A. Y chromosome microdeletions and alterations of spermatogenesis. *Endocr Rev.* 2001;22(2):226–39.
- De Palma A et al. Patients with abnormal sperm parameters have an increased sex chromosome aneuploidy rate in peripheral leukocytes. *Hum Reprod.* 2005;20(8):2153–6.
- Lissitsina J, Mikelsaar R, Punab M. Cytogenetic analyses in infertile men. *Arch Androl.* 2006;52(2):91–5.

24. Lee YS et al. Genital anomalies in Klinefelter's syndrome. *Horm Res.* 2007;68(3):150–5.
25. Ferlin A et al. Human male infertility and Y chromosome deletions: role of the AZF-candidate genes DAZ, RBM and DFFRY. *Hum Reprod.* 1999;14(7):1710–6.
26. Rucker GB et al. Preoperative screening for genetic abnormalities in men with nonobstructive azoospermia before testicular sperm extraction. *J Urol.* 1998;160(6 Pt 1):2068–71.
27. Tuerlings JH et al. Chromosome studies in 1792 males prior to intra-cytoplasmic sperm injection: the Dutch experience. *Eur J Hum Genet.* 1998;6(3):194–200.
28. Gunduz G, Luleci G, Baykara M. Cytogenetic study in 102 infertile men. *Urol Int.* 1998;61(1):32–4.
29. Rao L et al. Chromosomal abnormalities and y chromosome microdeletions in infertile men with varicocele and idiopathic infertility of South Indian origin. *J Androl.* 2004;25(1):147–53.
30. Nagvenkar P et al. Chromosomal studies in infertile men with oligozoospermia & non-obstructive azoospermia. *Indian J Med Res.* 2005;122(1):34–42.
31. Zhou-Cun A et al. Chromosomal abnormality and Y chromosome microdeletion in Chinese patients with azoospermia or severe oligozoospermia. *Yi Chuan Xue Bao.* 2006;33(2):111–6.
32. Pina-Neto JM et al. Somatic cytogenetic and azoospermia factor gene microdeletion studies in infertile men. *Braz J Med Biol Res.* 2006;39(4):555–61.
33. Meza-Espinoza JP et al. Chromosomal abnormalities in patients with azoospermia in Western Mexico. *Arch Androl.* 2006;52(2):87–90.
34. Samli H et al. Genetic anomalies detected in patients with non-obstructive azoospermia and oligozoospermia. *Arch Androl.* 2006;52(4):263–7.
35. Martinez-Garza SG et al. Genetic screening in infertile Mexican men: chromosomal abnormalities, Y chromosome deletions, and androgen receptor CAG repeat length. *J Androl.* 2008;29(6):654–60.
36. Balkan M, Tekes S, Gedik A. Cytogenetic and Y chromosome microdeletion screening studies in infertile males with Oligozoospermia and Azoospermia in Southeast Turkey. *J Assist Reprod Genet.* 2008;25(11–12):559–65.
37. Ceylan GG, Ceylan C, Elyas H. Genetic anomalies in patients with severe oligozoospermia and azoospermia in eastern Turkey: a prospective study. *Genet Mol Res.* 2009;8(3):915–22.
38. Akgul M et al. Cytogenetic abnormalities in 179 cases with male infertility in Western Region of Turkey: report and review. *J Assist Reprod Genet.* 2009;26(2–3):119–22.
39. Ng PP et al. Chromosomal anomalies and Y-microdeletions among Chinese subfertile men in Hong Kong. *Hong Kong Med J.* 2009;15(1):31–8.
40. Kumtepe Y et al. A genetic survey of 1935 Turkish men with severe male factor infertility. *Reprod Biomed Online.* 2009;18(4):465–74.
41. Kosar PA, Ozcelik N, Kosar A. Cytogenetic abnormalities detected in patients with non-obstructive azoospermia and severe oligozoospermia. *J Assist Reprod Genet.* 2010;27(1):17–21.
42. Mafra FA et al. Chromosomal and molecular abnormalities in a group of Brazilian infertile men with severe oligozoospermia or non-obstructive azoospermia attending an infertility service. *Int Braz J Urol.* 2011;37(2):244–50. discussion 250-1.
43. Akbari MT et al. Cytogenetic abnormalities in 222 infertile men with azoospermia and oligospermia in Iran: report and review. *Indian J Hum Genet.* 2012;18(2):198–203.
44. Kremer JA et al. Microdeletions of the Y chromosome and intracytoplasmic sperm injection: from gene to clinic. *Hum Reprod.* 1997;12(4):687–91.
45. Foresta C et al. High frequency of well-defined Y-chromosome deletions in idiopathic Sertoli cell-only syndrome. *Hum Reprod.* 1998;13(2):302–7.
46. Tse JY et al. A comparative study of Y chromosome microdeletions in infertile males from two Chinese populations. *J Assist Reprod Genet.* 2002;19(8):376–83.
47. SaoPedro SL et al. Prevalence of Y chromosome deletions in a Brazilian population of nonobstructive azoospermic and severely oligozoospermic men. *Braz J Med Biol Res.* 2003;36(6):787–93.
48. Omrani MD et al. Y chromosome microdeletions in idiopathic infertile men from West Azarbaijan. *Urol J.* 2006;3(1):38–43.
49. Arruda JT et al. Y chromosome microdeletions in Brazilian fertility clinic patients. *Genet Mol Res.* 2007;6(2):461–9.
50. Imken L et al. AZF microdeletions and partial deletions of AZFc region on the Y chromosome in Moroccan men. *Asian J Androl.* 2007;9(5):674–8.
51. Malekasgar AM, Mombaini H. Screening of 'Y' chromosome microdeletions in Iranian infertile males. *J Hum Reprod Sci.* 2008;1(1):2–9.
52. Stahl PJ et al. A decade of experience emphasizes that testing for Y microdeletions is essential in American men with azoospermia and severe oligozoospermia. *Fertil Steril.* 2010;94(5):1753–6.
53. Wang RX et al. Male infertility in China: laboratory finding for AZF microdeletions and chromosomal abnormalities in infertile men from Northeastern China. *J Assist Reprod Genet.* 2010;27(7):391–6.
54. Mirfakhraie R et al. High prevalence of AZFb microdeletion in Iranian patients with idiopathic non-obstructive azoospermia. *Indian J Med Res.* 2010;132:265–70.
55. Behulova R et al. Incidence of microdeletions in the AZF region of the Y chromosome in Slovak patients with azoospermia. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2011;155(1):33–8.
56. Krausz C et al. Double-blind Y chromosome microdeletion analysis in men with known sperm parameters and reproductive hormone profiles: microdeletions are specific for spermatogenic failure. *J Clin Endocrinol Metab.* 2001;86(6):2638–42.
57. Sadeghi-Nejad H, Farrokhi F. Genetics of azoospermia: current knowledge, clinical implications, and future directions. Part II: Y chromosome microdeletions. *Urol J.* 2007;4(4):192–206.
58. Simoni M, Bakker E, Krausz C. EAA/EMQN best practice guidelines for molecular diagnosis of y-chromosomal microdeletions. State of the art 2004. *Int J Androl.* 2004;27(4):240–9.
59. Vogt PH et al. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. *Hum Mol Genet.* 1996;5(7):933–43.
60. Krausz C, Quintana-Murci L, McElreavey K. Prognostic value of Y deletion analysis: what is the clinical prognostic value of Y chromosome microdeletion analysis? *Hum Reprod.* 2000;15(7):1431–4.
61. Cram DS, Osborne E, McLachlan RI. Y chromosome microdeletions: implications for assisted conception. *Med J Aust.* 2006;185(8):433–4.
62. Poongothai J, Gopenath TS, Manonayaki S. Genetics of human male infertility. *Singapore Med J.* 2009;50(4):336–47.
63. Scriven PN et al. Robertsonian translocations—reproductive risks and indications for preimplantation genetic diagnosis. *Hum Reprod.* 2001;16(11):2267–73.
64. Moradkhani K et al. Rare Robertsonian translocations and meiotic behaviour: sperm FISH analysis of t(13;15) and t(14;15) translocations: a case report. *Hum Reprod.* 2006;21(12):3193–8.
65. Aittomaki K et al. Safety issues in assisted reproduction technology: should ICSI patients have genetic testing before treatment? A practical proposition to help patient information. *Hum Reprod.* 2004;19(3):472–6.